Corcept Therapeutics Incorporated ( CORT Quick Quote CORT - Free Report) announced overall survival (“OS”) data from a phase II study evaluating its lead pipeline candidate, relacorilant, in combination with nab-paclitaxel for treating patients with recurrent platinum-resistant ovarian cancer.
Data from the study showed that women who received treatment with relacorilant plus nab-paclitaxel experienced 33% reduction in risk of death as compared to women treated with nab-paclitaxel alone.
Also, the median OS was 13.9 months for women who received relacorilant plus nab-paclitaxel versus 12.2 months for women receiving nab-paclitaxel monotherapy.
The company plans to begin a phase III study in the second quarter of 2022.
Shares of Corcept have rallied 22.1% so far this year against the
industry’s decline of 12.4%. Image Source: Zacks Investment Research
Corcept is also evaluating relacorilant in combination studies for treating other cancer indications.
Enrollment is also ongoing in the phase Ib study evaluating relacorilant in combination with
Merck’s ( MRK Quick Quote MRK - Free Report) PD-1 checkpoint inhibitor, Keytruda (pembrolizumab), for treating patients suffering from adrenal cancer along with cortisol excess.
Merck’s biggest revenue generator, Keytruda, is approved for treating several types of cancer indications. Merck is studying Keytruda for addressing yet more cancer indications.
Relacorilant, is also being evaluated in phase III of the GRACE study to treat Cushing’s syndrome. The company plans to submit a new drug application for relacorilant in the second quarter of 2023. Meanwhile, enrollment is underway in the phase III study of GRADIENT, evaluating relacorilant in patients whose Cushing’s syndrome is caused by adrenal adenoma.
Successful development of relacorilant for additional indications will be a boost to the company.
Corcept’s only marketed drug, Korlym, has been approved for the once-daily oral treatment of hyperglycemia — secondary to hypercortisolism — in adult patients with endogenous Cushing’s syndrome who are suffering from type II diabetes or glucose intolerance, and who have already failed surgery or are unsuitable for the same.
Korlym generated sales worth $366 million in 2021, reflecting an increase of 3.4% year over year.
Zacks Rank & Stocks to Consider
Corcept currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the same sector are
Onconova Therapeutics, Inc. ( ONTX Quick Quote ONTX - Free Report) and Corbus Pharmaceuticals Holdings, Inc. ( CRBP Quick Quote CRBP - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see . the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
Onconova Therapeutics’ loss per share estimates have narrowed 35.6% for 2022 and 28% for 2023 over the past 60 days.
Earnings of Onconova Therapeutics have surpassed estimates in each of the trailing three quarters. ONTX has an average earnings surprise of 22.72%.
Corbus Pharmaceuticals’ loss per share estimates have narrowed 19.4% for 2022 and 16.2% for 2023 over the past 60 days.
Earnings of Corbus Pharmaceuticals have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. CRBP has delivered an average earnings surprise of 23.07%.